Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,

Slides:



Advertisements
Similar presentations
San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.
Advertisements

MODELS OF SYSTEMIC TREATMENT IN BREAST CANCER
Integration of Taxanes in the Management of Breast Cancer
Locally Advanced and Metastatic Disease
Oncologic Drugs Advisory Committee
Bevacizumab taxan Första linjens behandling vid metastaserande Her2- bröstcancer.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer Julie R. Gralow, M.D. Director and Jill Bennett Professor of Breast Medical.
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
ANTRACICLINE: evoluzione di un farmaco ROMA, 6 Febbraio 2009 – CAMPUS BIO-MEDICO SCHEDULE SETTIMANALI CON ANTRACICLINE Maria Sofia Rosati UOC Oncologia.
1 When all you have is a hammer… Endocrine therapy Chemotherapy Targeted therapies Radiotherapy.
Advances in Adjuvant Systemic Therapy of Breast Cancer
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
1 Approaches to Metastatic Disease in Breast Cancer Anne F. Schott, MD University of Michigan.
Memorial Sloan-Kettering Cancer Center
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Drug Treatment of Metastatic Breast Cancer
First Safety Data from a Randomized Phase III (CIBOMA/ /GEICAM ) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard.
Current Therapy of Metastatic Breast Cancer Julie R. Gralow, M.D Assistant Professor, Medicine/Oncology University of Washington School of Medicine Fred.
Treatment of Refractory Ovarian Cancer
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Medical Oncology Training Program Resident Teaching Friday January 7th, PMH, Locally Advanced and Inflammatory Breast Cancer Eitan Amir Medical.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Shanghai, China March 24 th 2001 Xeloda Future Developments Mr. John Collins.
RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.
Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate This program is supported by an educational grant from.
Investigating the Role of Anti- Angiogenic Agents in Ovarian Cancer Carol Aghajanian, M.D. Chief, Gynecologic Medical Oncology Memorial Sloan-Kettering.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True: Clara Natoli.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
Educational Objectives Metastatic Breast Cancer: Scope of the Problem.
Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
Highlights in the Management of Breast Cancer CINBO Consorzio Interuniversitario Nazionale per la Bio-Oncologia “Taxanes vs Anthra-containing chemotherapy.
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.
Terapia Neoadiuvante Revisione delle evidenze scientifiche
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Activity of Epothilones in Breast Cancer and Other Tumor Types Sandra M. Swain, MD Professor of Medicine Uniformed Services University of Health Sciences.
FinXX trial Authors: Sunil Verma Date posted: December 22 nd, 2008.
Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
R2 김형오 / Pf. 김시영.  Recent results  Presence of extensive lymphocytic infiltration in early stage breast cancer  Good prognosis  High response rates.
Challenges for the treatment of breast cancer
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB.
Management of metastatic and recurrent head and neck cancer
Azienda Ospedaliero Universitaria Policlinico Modena
ABRAMYO Phase I-II study of weekly nab paclitaxel in combination with liposomal encapsulated doxorubicin in patients with HER2 negative MBC Alessandra.
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
DR VANDERPUYE CONSULTANT RADIATION AND CLINICAL ONCOLOGIST GHANA
CONFIDENTIAL Public observers
Caris Molecular Intelligence®
OPTIMIZING NEOADJUVANT/ADJUVANT TREATMENT OPTIONS IN PATIENTS WITH BREAST CANCER DR LASEBIKAN NWAMAKA RADIATION AND CLINICAL ONCOLOGIST UNTH.
No F in FEC?.
Krop I et al. SABCS 2009;Abstract 5090.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised.
Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.
Volume 373, Issue 9676, Pages (May 2009)
GASTRIC CANCER 2007 #New Cases (rank) # Deaths (rank)
Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy  Yuh-Min Chen, MD, PhD, Reury-Perng Perng, MD, PhD, Jen-Fu.
Presentation transcript:

Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin, Caelyx. Capecitabine / 5 FU Eribulin Vinorelbine Gemcitabine Ixabepilone Etoposide Cyclophosphamide Methotrexate Platinum agents Combination Chemotherapy High Dose Chemotherapy and Stem Cell Transplant – no benefit.

Common Adjuvant Regimens First Generation → Second Generation → Third Generation CMF*6 → CAF*6, CEF*6 CMF*6 → FAC*6 → TAC*6 CE(50)F*6 → CE(100)F*6 → FEC*3 →D*3 AC*4 → AC*4 → Txl*4 q3wk → Dose Dense (CA*4 → Txl*4 q2wk) AC*4 → TC*4 20%

RANDOMIZERANDOMIZE Doxorubicin 60 mg/m2 IV Day 1 Cyclophosphamide600 mg/m2 IV Day 1 Every 21 days x 4 cycles Docetaxel 75 mg/m2 IV Day 1 Cyclophosphamide600 mg/m2 IV Day 1 Every 21 days x 4 cycles

4 2 nd Generation Adjuvant Chemo Trials First Generation → Second Generation → Third Generation CMF*6 → CAF*6, CEF*6 CMF*6 → FAC*6 → TAC*6 CE(50)F*6 → CE(100)F*6 → FEC*3→D*3 AC*4 → AC*4 → Txl*4 q3wk → Dose Dense (CA*4 → Txl*4 q2wk) AC*4 → TC*4

5

8 What’s the Goal? Select patients who will require systemic therapy Find predictive factors (either before or early in treatment) that allow for accurate tailoring of therapy

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25